MYOSITIS ASSOCIATED INTERSTITIAL LUND DISEASE (MA-ILD)

Clinical trials for MYOSITIS ASSOCIATED INTERSTITIAL LUND DISEASE (MA-ILD) explained in plain language.

Never miss a new study

Get alerted when new MYOSITIS ASSOCIATED INTERSTITIAL LUND DISEASE (MA-ILD) trials appear

Sign up with your email to follow new studies for MYOSITIS ASSOCIATED INTERSTITIAL LUND DISEASE (MA-ILD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New drug combo aims to slow lung damage in rare muscle disease

Disease control Completed

This study tested whether adding nintedanib (OFEV) to standard immunosuppressant therapy can improve symptoms in people with myositis-associated interstitial lung disease, a condition where lung tissue becomes scarred and stiff. 49 adults in the U.S. participated, receiving eithe…

Matched conditions: MYOSITIS ASSOCIATED INTERSTITIAL LUND DISEASE (MA-ILD)

Phase: PHASE4 • Sponsor: Rohit Aggarwal, MD • Aim: Disease control

Last updated Jun 27, 2026 09:07 UTC

MYOSITIS ASSOCIATED INTERSTITIAL LUND DISEASE (MA-ILD)

Get alerted when new MYOSITIS ASSOCIATED INTERSTITIAL LUND DISEASE (MA-ILD) trials appear

New drug combo aims to slow lung damage in rare muscle disease